Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (Nasdaq: ALGS) reported its Q3 2021 financial results, revealing a net loss of $33.1 million, slightly lower than the $33.3 million loss in Q3 2020. R&D expenses rose to $28.1 million from $17.3 million, driven by ongoing clinical trials for its hepatitis B therapies. The company is advancing its drug candidates, including ALG-020572 and ALG-055009, with patient enrollment progressing. Notably, cash reserves stand at $242.7 million, maintaining a stable financial position despite increased expenditures.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that it will release its third quarter 2021 financial results on November 4, 2021, following U.S. market close. Founded in 2018, Aligos is a clinical-stage biopharmaceutical company aiming to lead in treatments for viral infections and liver diseases. The company is focused on developing targeted antiviral therapies for chronic hepatitis B and coronaviruses, alongside therapeutics for nonalcoholic steatohepatitis (NASH).

Aligos Therapeutics (Nasdaq: ALGS) announced its participation in The Liver Meeting® 2021, presenting data on chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) programs. The virtual event will take place from November 12-15, 2021. Key presentations include:

• Safe and effective Capsid Assembly Modulator (ALG-000184) for CHB
• Innovative Antisense Oligonucleotides showing significant efficacy
• Preclinical results for treatment of NASH with ALG-055009.

All poster data will be available post-conference on the Aligos website.

Aligos Therapeutics (Nasdaq: ALGS) is advancing three of its four drug candidates for chronic hepatitis B (CHB) to clinical trials. The latest candidate, ALG-020572, is being evaluated in a Phase 1 study starting with healthy volunteers. This proprietary antisense oligonucleotide aims to lower HBsAg levels, potentially leading to a functional cure in CHB patients. Aligos believes that ALG-020572 might possess enhanced antiviral activity compared to other candidates. The company is also pursuing various mechanisms within its CHB portfolio for improved treatment outcomes.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company, announced that its Chairman and CEO, Lawrence M. Blatt, Ph.D., MBA, will present at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. The presentation is scheduled for September 27, 2021, from 1:20 PM to 1:50 PM Eastern Time.

Investors can access the webcast here, with a replay available for 90 days post-event. Aligos focuses on addressing viral and liver diseases through innovative therapeutics.

Aligos Therapeutics (NASDAQ: ALGS) announced an $83.6 million gross proceeds from a public offering of common stock. Key advancements include ongoing clinical trials for CHB drug candidates STOPS™ and CAM programs, with initial data shared at scientific conferences. The company has filed a clinical trial application for its third CHB drug, ALG-020572, expecting to commence dosing in Q4 2021. Financially, Aligos reported a Q2 2021 net loss of $29.8 million and increasing R&D expenses, totaling $24.6 million.

Aligos Therapeutics (Nasdaq: ALGS) will release its second quarter 2021 financial results on August 5, 2021, after U.S. market close. The company, established in 2018, focuses on developing innovative therapies for viral infections and liver diseases. Its strategy leverages extensive expertise in drug development, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Aligos aims to advance potentially best-in-class molecules in its pipeline to meet significant unmet medical needs.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the pricing of its public offering of 4,400,000 shares at $19.00 per share, aiming for gross proceeds of approximately $83.6 million. The underwriters have a 30-day option to purchase 660,000 additional shares. The offering closings are expected by July 6, 2021, subject to conditions. This move supports Aligos' mission to develop antiviral therapies for chronic hepatitis B and liver diseases.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) has announced a public offering of 4,000,000 shares of common stock, with an additional 600,000 shares available for underwriters. The offering is contingent upon market conditions and is managed by J.P. Morgan, Jefferies, and Piper Sandler. A registration statement has been filed with the SEC, but remains unapproved. Aligos aims to lead in treatments for viral infections and liver diseases, focusing on chronic hepatitis B and nonalcoholic steatohepatitis. The company emphasizes potential risks related to market conditions and drug development uncertainties.